Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000531736 | SCV000623251 | uncertain significance | Bloom syndrome | 2024-12-28 | criteria provided, single submitter | clinical testing | This variant, c.1856_1858del, results in the deletion of 1 amino acid(s) of the BLM protein (p.Phe619del), but otherwise preserves the integrity of the reading frame. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with BLM-related conditions. ClinVar contains an entry for this variant (Variation ID: 454088). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000562774 | SCV000672969 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-12-14 | criteria provided, single submitter | clinical testing | The c.1856_1858delTCT variant (also known as p.F619del) is located in coding exon 6 of the BLM gene. This variant results from an in-frame TCT deletion at nucleotide positions 1856 to 1858. This results in the in-frame deletion of a phenylalanine at codon 619. The deleted amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be neutral by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000531736 | SCV002092402 | uncertain significance | Bloom syndrome | 2018-06-19 | no assertion criteria provided | clinical testing |